Figure 1




Figure 2



mAU
400
350
300
250
200
150
100
50
0
6.838
0
2.5
5
7.5
10
12.5
15
17.5
20
22.5
min

Figure 3




Figure 4




Figure 5A



CR 2012-08-27 R timecourse DN #49 [modified by labuser] HC-T110-4h
UV VIS_1
WVL:214 nm
mAU
min
HC T110
P0
P1
P2
unconjugated,24.15
singly,42.40
doubly,19.95
1
5
180
100
50
-20
2.50
3.00
4.00
5.00
6.00
7.00
8.00
9.00
9.50

Figure 5B





UV VIS 1
WL:214 nm
CR 2012-08-27 R timecourse DN #41 [modified by labuser, 2 peaks manually assigned]
mAU
300
200
100
-40
2.50
3.00
4.00
5.00
6.00
7.00
8.00
9.00
9.50
min
HC S112
P0
P1
P2
unconjugated, 4.48
singly, 47.07
doubly, 36.81
1
5


Figure 6




6A




6B


HC T77
AUC, % Total
100
80
60
40
20
0
0
5
10
15
20
Time(h)

6C


HC Y79
AUC, % Total
100
80
60
40
20
0
0
5
10
15
20
Time(h)
Unconjugated
Singlly
Doubly

6D


100
80
60
40
20
0
AUC, %Total
0
5
10
15
20
Time(h)
Unconjugated
Singlly
Doubly

6E

Figure 7A



Suppression Effiency of pAzF v. pAzMeF
pAzF
pAzMeF
% Suppression (compared to wt)
400%
350%
300%
250%
200%
150%
100%
50%
0%
HC-S25
HC-I51
HC-S70
HC-Y79
HC-F126
HC-K222
LC-minus 1
LC-P8
LC-T22
LC-R142
LC-N138
wt

Figure 7B



Soluble IgG Yield of pAzF v. pAzMeF
pAzF
pAzMeF
Soluble IgG, ug/mL
0
10
20
30
40
50
60
HC-S25
HC-I51
HC-S70
HC-Y79
HC-F126
HC-K222
LC-minus 1
LC-P8
LC-T22
LC-R142
LC-N138
wt

Figure 8



Karpas 299
cell viability (% of control)
120
100
80
60
40
20
0
0.0001 0.001 0.01 0.1 1 10
nM
Adcetris HC F404 unconjugated
Adcetris HC K121 unconjugated
Adcetris LC N152 unconjugated
Adcetris HC F404 AB4285
Adcetris HC K121 AB4285
Adcetris LC N152 AB4285
L540
cell viability (% of control)
120
100
80
60
40
20
0
0.0001 0.001 0.01 0.1 1 10
nM
Adcetris HC F404 unconjugated
Adcetris HC K121 unconjugated
Adcetris LC N152 unconjugated
Adcetris HC F404 AB4285
Adcetris HC K121 AB4285
Adcetris LC N152 AB4285

Figure 9



SKBR3
cell viability (% of control)
120
100
80
60
40
20
0
0.001
0.01
0.1
1
10
100
1000
10000
Sutroceptin HC F404 AB4285
Sutroceptin WT
Adcetris HC F404 AB4285
Adcetris HC K121 AB4285
Adcetris LC N152 AB4285
AB4285 free drug
Raji
cell viability (% of control)
Sutroceptin HC F404 AB4285
Adcetris HC F404 AB4285
Adcetris HC K121 AB4285
Adcetris LC N152 AB4285
AB4285 free drug
Jurkat
cell viability (% of control)
Sutroceptin HC F404 AB4285
Adcetris HC F404 AB4285
Adcetris HC K121 AB4285
Adcetris LC N152 AB4285
AB4285 free drug
nM

Figure 10



Karpas
120
100
80
60
40
20
0
% binding
0.01
0.1
1
10
100
nM
Adcetris HC F404 AB4285
Adcetris HC K121 AB4285
Adcetris LC N152 AB4285
L540
120
100
80
60
40
20
0
% binding
0.01
0.1
1
10
100
nM
Adcetris HC F404 unconjugated
Adcetris HC K121 unconjugated
Adcetris LC N152 unconjugated
Adcetris HC F404 AB4285
Adcetris HC K121 AB4285
Adcetris LC N152 AB4285

Figure 11

Figure 11A: DBCO-MMAF 2




Figure 11B: DBCO-DM4




Figure 11C: DBCO-DM4 2




Figure 11D: DBCO-MMAE




Figure 12



100
10
1
0.1
Plasma IgG Concentrations (µg/mL)
0
5
10
15
20
25
30
Time (days)
ScFv-Fc R355 MMAF2
ScFv-Fc N389 MMAF2

Figure 13a




Figure 13b

